OnKure Therapeutics, Inc. OKUR Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $2.82M+13.0% | $3.43M+100% | $4.07M+372% | $3.22M+146% | $2.49M+64.7% | ||
| $46.96M-2.7% | $48.26M+10.2% | $51.9M— | $50.1M— | $48.24M— | ||
| $14.61M+9.7% | $14.69M+38.7% | $15.62M— | $13.43M— | $13.31M— | ||
| $61.57M0.0% | $62.95M+15.7% | $67.52M— | $63.54M— | $61.55M— | ||
| -$61.57M0.0% | -$62.95M-15.7% | -$67.52M— | -$63.54M— | -$61.55M— | ||
| -$58.75M+0.5% | -$59.52M-13.0% | -$63.46M— | -$60.31M— | -$59.06M— | ||
| -$4.33— | -$4.41— | —— | —— | —— | ||
| -$61.13M-0.1% | -$62.5M-15.9% | -$67.07M— | -$63.07M— | -$61.09M— | ||
| -$61.57M0.0% | -$62.95M-15.7% | -$67.52M— | -$63.54M— | -$61.55M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is OnKure Therapeutics, Inc. profitable?
- OnKure Therapeutics, Inc. is not currently profitable: it reported a net loss of $58.7M over the trailing twelve months.
- What is OnKure Therapeutics, Inc.'s earnings per share?
- OnKure Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-4.33.
- Where does OnKure Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from OnKure Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.